According to Zhitong Finance App, Kanghong Pharmaceutical (002773.SZ) issued an announcement. On April 28, 2024, the KH658 ophthalmic injection declared by the company's subsidiary Chengdu Hongji Biotechnology Co., Ltd. obtained an approval notice for drug clinical trials from the China Drug Administration and agreed to carry out phase I/II clinical trials.
According to reports, KH658 ophthalmic injection is the second product of Hongji Biotech to be approved for clinical trials in China and the US at the same time. It uses a novel adeno-associated virus with independent intellectual property rights and a cell-specific receptor design as a delivery carrier. It has the characteristics of simple administration, safety, and high cell transduction efficiency. By continuously expressing anti-VEGF protein in the human body, this product inhibits the growth of neovascularization and slows the progression of the disease. It is expected that patients will benefit in the long term with a single dose.